Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index

Thursday, June 26, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CORAL GABLES, Fla., June 25 CatalystPharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it is set tojoin the Russell Microcap(R) Index when Russell Investments reconstitutes itsfamily of U.S. indexes on June 27, 2008, according to a preliminary list ofadditions posted on June 13, 2008 on .

Membership in the Russell Microcap Index, which remains in place for oneyear, means automatic inclusion in the appropriate growth and value styleindexes. Russell determines membership for its equity indexes primarily byobjective, market-capitalization rankings and style attributes.

Patrick J. McEnany, Chief Executive Officer of Catalyst, noted, "We arepleased that the Company's shares are being added to the Russell MicrocapIndex. We view this as recognition of Catalyst's numerous accomplishments overthe past year, which have translated into increased market value for ourshareholders. Among other milestones during the remainder of the year, we lookforward to reporting top line results for our U.S. Phase II clinical trialevaluating our lead compound, CPP-109, as a treatment for cocaine addiction,as well as the initiation of a U.S. Phase II clinical trial for CPP-109 as apotential treatment for methamphetamine addiction. Catalyst is dedicated tobringing innovative therapies to market for the treatment of both drugaddiction as well as obsessive compulsive disorders and our inclusion in theRussell Microcap Index should help to expand the Company's visibility andinvestor base even further."

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largestU.S. stocks as of the end of May, ranking them by total market capitalizationto create the Russell 3000(R) Index and the Russell Microcap(R) Index. Russellindexes are widely used by investment managers and institutional investors forindex funds and as benchmarks for both passive and active investmentstrategies. An industry-leading $4.4 trillion in assets currently arebenchmarked to them. These investment tools originated from Russell'smulti-manager investment business in the early 1980s when the company saw theneed for a more objective, market-driven set of benchmarks in order toevaluate outside investment strategies.

About Russell

Russell Investments aims to improve financial security for people byproviding strategic advice, world-class implementation, state-of-artperformance benchmarks, and a range of institutional-quality investmentproducts. With more than $213 billion in assets under management, Russellserves individual, institutional and advisor clients in more than 40countries. Russell provides access to some of the world's best money managers.It helps investors put this access to work in corporate defined benefit anddefined contribution places, and in the life savings of individual investors.Headquartered in Tacoma, Wash., Russell has principal offices in Amsterdam,Auckland, Johannesburg, London, Melbourne, New York, Paris, San Francisco,Seoul, Singapore, Sydney, Tokyo and Toronto. For more information on Russellindexes, go to .

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical companyfocused on the development and commercialization of prescription drugs for thetreatment of addiction and obsessive compulsive disorders. The Company hasobtained from Brookhaven National Laboratory an exclusive worldwide licensefor Brookhaven's patent portfolio in the United States relating to the rightto use vigabatrin to treat a wide variety of substance addictions andobsessive compulsive disorders. Catalyst has also been granted rights toBrookhaven's vigabatrin-related foreign patents or patents pending in morethan 30 countries. The Company's initial product candidate based on vigabatrinis CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &Drug Administration (FDA)

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store